| Name | Title | Contact Details |
|---|
CareCentrix is a leader in managing care to the home. Headquartered in Hartford, Conn., CareCentrix connects patients with the care they need at home, through a national network of over 8,000 credentialed provider locations providers, with customer care centers located across the United States. CareCentrix provides optimal access to quality home care for more than 23 million lives by connecting providers with patients and helping them navigate the complex home care system. CareCentrix`s extensive range of services provides support and coordination for patients and their families in every step of the healing process, including home health, durable medical equipment (DME), home infusion, sleep management and care management services, which ultimately improve care transitions and reduce unnecessary readmissions and emergency room visits.
Lyniate offers industry-leading interoperability solutions that deliver simple and seamless integration of all health data. With two Best-in-KLAS products, Lyniate Corepoint and Lyniate Rhapsody, we established a proven reputation on which we continue to build adaptable interoperability solutions that connect the healthcare ecosystem to unlock the full potential of data. We partner with providers, health plans, and health tech solutions around the world to enable rapid, reliable, and scalable interoperability, both vertically and horizontally, on-premises and in the cloud.
Imed Software Corporation is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Beacon Specialized Living is a company that provides assisted living facilities and behavioral healthcare services for developmentally disabled, mentally ill, and autistic adults.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.